Literature DB >> 11799848

Molecular factors affecting the complex formation between deferiprone (L1) and Cu(II). Possible implications on efficacy and toxicity.

I Pashalidis1, G J Kontoghiorghes.   

Abstract

Deferiprone (1,2-dimethyl-3-hydroxypyrid-4-one, L1, CAS 30652-11-0) is a new chelating drug used worldwide for the treatment of iron overloading conditions. Spectrophotometric and potentiometric measurements were carried out to investigate the interaction of L1 with Cu(II) ions under different conditions. The complexation of Cu(II) ions with L1 in aqueous solution leads predominantly to the formation of the Cu(L1)2 species at a pH range of 4-9. The experimental results indicate that L1 has high affinity for Cu(II) with stability constants log beta 11 = 10.3 +/- 0.9 and log beta 12 = 19.2 +/- 0.6. The effect of Cu(II) ions on the affinity of L1 for Fe(III) ions by competition reactions in vitro indicate displacement of Fe(III) in a concentration dependent manner by Cu(II). Similarly, the presence of different buffers at various pH values resulted in the formation of different stoichiometry L1 complexes with Cu(II) and of mixed complexes with buffer anions. The strong interaction of L1 with Cu(II) may have implications on the therapeutic and toxicological properties of this chelating drug. In particular, L1 may be used in the treatment of copper overloading conditions, such as Wilson's disease or other conditions where copper toxicity is implicated.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11799848     DOI: 10.1055/s-0031-1300151

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  6 in total

1.  Effective inhibition of copper-catalyzed production of hydroxyl radicals by deferiprone.

Authors:  V A Timoshnikov; T Kobzeva; O Y Selyutina; N E Polyakov; G J Kontoghiorghes
Journal:  J Biol Inorg Chem       Date:  2019-03-13       Impact factor: 3.358

2.  Interactions of the pyridine-2-carboxaldehyde isonicotinoyl hydrazone class of chelators with iron and DNA: implications for toxicity in the treatment of iron overload disease.

Authors:  Timothy B Chaston; Des R Richardson
Journal:  J Biol Inorg Chem       Date:  2003-02-05       Impact factor: 3.358

Review 3.  Benefits and risks of deferiprone in iron overload in Thalassaemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamine.

Authors:  George J Kontoghiorghes; Katia Neocleous; Annita Kolnagou
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

Review 4.  Copper Dyshomeostasis in Neurodegenerative Diseases-Therapeutic Implications.

Authors:  Grażyna Gromadzka; Beata Tarnacka; Anna Flaga; Agata Adamczyk
Journal:  Int J Mol Sci       Date:  2020-12-04       Impact factor: 5.923

Review 5.  Mechanistic Insights of Chelator Complexes with Essential Transition Metals: Antioxidant/Pro-Oxidant Activity and Applications in Medicine.

Authors:  Viktor A Timoshnikov; Olga Yu Selyutina; Nikolay E Polyakov; Victoria Didichenko; George J Kontoghiorghes
Journal:  Int J Mol Sci       Date:  2022-01-23       Impact factor: 5.923

Review 6.  Current Biomedical Use of Copper Chelation Therapy.

Authors:  Silvia Baldari; Giuliana Di Rocco; Gabriele Toietta
Journal:  Int J Mol Sci       Date:  2020-02-06       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.